This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie,
not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose
levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It
will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed
WHO essential medicine, can protect the lung and liver against oxidative damage, preserve
lung function, and accelerate the eradication of MTB infection by replenishing glutathione
(GSH).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Aurum Institute NPC
Collaborators:
Global Alliance for TB Drug Development Instituto Nacional de Saúde, Mozambique Ludwig-Maximilians - University of Munich National Institute for Medical Research, Tanzania Sequella, Inc. Stichting Katholieke Universiteit University of Stellenbosch Wits Health Consortium (Pty) Ltd